

Effect of Blood Flow by Botulinum Toxin Injection for Severe Peripheral Artery Occlusive Disease

NCT06878482

Status	RECRUITING
Phase	Phase 4
Sponsor	Yonsei University
Enrollment	15 participants

Key Eligibility Criteria

Inclusion (6)

- Age e 20 years old
- Patients who have a lower extremity wound among those who have been diagnosed with moderate or severe lower extremity ischemia
- Patients who are unable to perform additional procedures (angioplasty, etc.) by performing peripheral vascular examination and CT angiography
- Wound size e 1x1cm² to d 3x3cm²
- Patients who can follow the clinical trial procedure well and abide by the visit schedule
- ... and 1 more (see full listing online)

Exclusion (12)

- Patients with diseases that can affect neuromuscular function, such as myasthenia gravis, Eaton-Lamberton syndrome, amyotrophic lateral sclerosis, and motor neuropathy
- Within 4 weeks before screening, aminoglycoside antibiotics, curare-like agents, or drugs that inhibit neuromuscular function (muscle relaxants, anticholinergics, benzodiazepines, benzamides, tetracyclines, Rinco Those who have taken mycin antibiotics, etc.)
- Those taking aspirin, NSAIDs or anticoagulants within 7 days before screening
- Those who have received botulinum toxin preparations within 3 months before screening
- Angiography or CT angiography If one or more of the three major blood vessels in the lower extremity are open
- ... and 7 more (see full listing online)

Locations (1 total)

Yongin Severance Hospital, Yongin-si, Gyeonggi-do, South Korea